NEW YORK – Cancer Genetics reported on Monday that its fourth quarter revenues grew about 12 percent year over year, which the firm noted was partially the result of the adoption of the new ASC 606 revenue recognition standard and the variability in project start and end times at the individual contract level in the firm's discovery services business unit.
For the three months ended Dec. 31, 2019, the firm reported total revenues from continuing operations of $1.9 million, up from $1.7 million in the fourth quarter of 2018.